NCNA vs NKTX

NuCana plc vs Nkarta, Inc. — Valuation Comparison 2026

NCNA

Biotechnology
NuCana plc
Quality
1.7
out of 10
Value Trap
Price
$2.27
Last close
Models
6/13
Active
VS

NKTX

Biotechnology
Nkarta, Inc.
Quality
4.6
out of 10
Value Trap
18
SAFE
Price
$3.30
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType NCNA Fair ValueNCNA Upside NKTX Fair ValueNKTX Upside
Bayesian DCF Intrinsic $0.60 -73.5% $0.66 -80.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.98 +85.3% $2.32 -29.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NCNA vs NKTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NCNA vs NKTX — Which Stock Is More Undervalued?

NKTX scores higher with a 4.6/10 quality rating vs NCNA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NuCana plc (NCNA) and Nkarta, Inc. (NKTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NCNA currently trades at $2.27 with a QOC of 1.7/10, while NKTX trades at $3.30 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).